FEATURED
FDA issues third CRL to Aldeyra, rejecting reproxalap NDA

Agency notes a lack of substantial evidence, failure to demonstrate efficacy, and inconsistent study results in latest dismissal of the DED eye drop.

Earn FREE CE 24/7 with Courses by Eyes On Eyecare

Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.

TRENDING
Research